Abbott Laboratories and Raven biotechnologies Establish Research Collaboration For Antibody Therapeutics
"We are extremely pleased to partner with Abbott. Their capabilities and commitment to therapeutic antibodies for oncology greatly enhance the potential of moving Raven's therapeutics into the clinic," said Jennie P. Mather, Ph.D., Founder, President and CEO of Raven. "We view this collaboration as a strong endorsement of our unique approach of using cell- based discovery methods to identify novel cancer targets and to rapidly obtain biologically active antibody drugs."
"This collaboration with Raven underscores Abbott's strong commitment to immunotherapeutics and to finding potential new treatment options for cancer patients," said Stephen W. Fesik, Ph.D., Divisional Vice President, Cancer Research, Abbott Laboratories. "Abbott's leadership in monoclonal antibody research coupled with Raven's discovery capabilities will help us bring effective new treatments to patients."
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous